This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Hatteras Venture Partners | |
|---|---|
| Name | Hatteras Venture Partners |
| Type | Private |
| Founded | 2003 |
| Founders | Charles Hargrave; Ben Rooks |
| Headquarters | Raleigh, North Carolina |
| Industry | Venture capital |
| Products | Private equity |
| Assets | US$1.2 billion (2023) |
Hatteras Venture Partners is a venture capital firm based in Raleigh, North Carolina that invests in early-stage and growth-stage companies across technology, healthcare, and consumer markets. The firm participates in seed, Series A, and later rounds and has been involved with companies that have undergone IPOs, mergers, and acquisitions. Hatteras maintains ties to academic ecosystems and regional innovation networks while engaging with national investors and limited partners.
Hatteras Venture Partners operates as a limited partnership that raises funds from pension funds, endowments, family offices, and corporate investors to deploy capital into startup and growth-stage companies. The firm targets sectors including enterprise software, biotechnology, medical device, and consumer Internet and leverages relationships with research universities such as North Carolina State University and Duke University. Hatteras combines board representation, strategic guidance, and follow-on financing to pursue exits via initial public offering, strategic acquisition by corporations like Cisco Systems or Thermo Fisher Scientific, or secondary sales to private equity firms.
Founded in 2003, Hatteras emerged during a period of renewed venture activity following the dot-com bubble aftermath and in parallel with growth in the Research Triangle Park cluster. Early investments aligned with the expansion of biotech and software startups incubated by institutions such as University of North Carolina at Chapel Hill and accelerators exemplified by Y Combinator. Over time the firm expanded its geographic reach to the Research Triangle, Charlotte, North Carolina, and select West Coast opportunities near Silicon Valley and San Francisco. Hatteras has participated in rounds alongside prominent firms including Sequoia Capital, Accel Partners, Benchmark, and Andreessen Horowitz.
Hatteras emphasizes sector specialization and stage flexibility, allocating capital across seed, Series A, and growth rounds. The firm's due diligence draws on networks within Duke University School of Medicine, UNC Health, and technical talent from North Carolina State University College of Engineering. Portfolio construction balances healthcare exposure—via biopharmaceutical and medical device firms—with enterprise exposure—via cloud computing, software as a service, and cybersecurity ventures. Hatteras often co-invests with strategic corporate venture arms such as Intel Capital and Google Ventures, and works with limited partners including Teacher Retirement System of Texas-type institutional allocators. The firm pursues exits through IPOs to exchanges such as the NASDAQ and New York Stock Exchange and strategic acquisitions by firms including Johnson & Johnson and Medtronic.
Hatteras has backed a range of companies across sectors and stages, often joining syndicates with firms like Kleiner Perkins and Lightspeed Venture Partners. Notable portfolio companies have included startups that scaled to IPOs or were acquired by industry leaders. These companies have operated in domains such as genomics and diagnostics, cloud-native infrastructure and application security, and consumer marketplaces. Hatteras’s investments intersect with companies that have engaged with corporate partners like Pfizer, Amazon Web Services, and IBM and regulatory pathways involving agencies such as the Food and Drug Administration. The firm’s backing has extended to ventures that participated in accelerator programs run by Techstars and 500 Startups.
Hatteras raises discrete venture funds, each structured as a closed-end vehicle with a typical life of ten years and provisions for extension. Fund sizes have varied across vintages, reflecting shifts in strategy and market conditions; limited partners have included university endowments, insurance companies, and sovereign wealth-style allocators. Performance metrics for funds are reported as pooled internal rates of return and multiples of invested capital, benchmarking against indices like the Cambridge Associates venture median and MSCI-linked performance sets. Exit events—both IPOs and strategic sales—contribute to distributions to limited partners, while follow-on rounds are often syndications with later-stage investors such as Tiger Global Management and SoftBank Vision Fund.
The firm’s leadership team comprises general partners, venture partners, and operating partners with backgrounds in entrepreneurship, investment banking, and corporate management. Key figures have prior affiliations with firms and institutions such as Goldman Sachs, Morgan Stanley, General Electric, and academic appointments at Duke University or North Carolina State University. Advisors include former executives from Medtronic, Roche, and Oracle Corporation, as well as technologists who have been founders in Silicon Valley startups. The board-level involvement of partners often connects portfolio companies with executives from IBM and Cisco Systems for scaling operations and international expansion.
Like many venture firms, Hatteras has been subject to disputes over fund governance, carried interest allocation, and limited partner communications. Legal matters involving venture firms commonly touch on partnership agreement interpretation, fiduciary duties, and claims related to disclosure of conflicts of interest with co-investors or affiliated vehicles. Such disputes can draw upon precedent set in cases involving firms such as Sequoia Capital and Blackstone-adjacent litigation, and may involve arbitration forums preferred by limited partner agreements and rulings in state courts like those of Delaware. Regulatory scrutiny by agencies including the Securities and Exchange Commission can arise in contexts of IPO preparation and secondary sales.
Category:Venture capital firms